Arcutis Biotherapeutics (ARQT) announced that its wholly-owned subsidiary Arcutis Canada, Inc. has received regulatory approval from Health Canada for ZORYVE topical foam 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older. The approval of ZORYVE foam 0.3% for seborrheic dermatitis in Canada was supported by results from a vehicle-controlled pivotal Phase 3 study, as well as a Phase 2 study, a long-term open-label extension study, and a Phase 1 pharmacokinetic study.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis announces new pooled subgroup analysis results from INTEGUMENT-1 trial
- Arcutis Biotherapeutics announces FDA accepted its sNDA for ZORYVE foam
- Arcutis Biotherapeutics annonnces publication of ZORYVE in JAMA Dermatology
- Arcutis Biotherapeutics completes enrollment of Phase 1b study on ARQ-255
- Arcutis announces results from INTEGUMENT-OLE study of roflumilast cream